SCHEMBL23218353

SCHEMBL23218353

CCOC(=O)c1coc2c(CN3CCN(C(=O)OC(C)(C)C)CC3)cc(Br)cc12

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP1 P03956 1/20 0.43
MMP9 P14780 1/20 0.43
MMP13 P45452 1/20 0.43
ADAM17 P78536 1/20 0.43
VEGFA P15692 1/20 0.40
EGLN1 Q9GZT9 1/20 0.40
ALDH1A1 P00352 8/20 0.39
KDM4E B2RXH2 6/20 0.39
POLB P06746 2/20 0.39
TSHR P16473 2/20 0.39
CA12 O43570 1/20 0.38
CA1 P00915 1/20 0.38
CA2 P00918 1/20 0.38
CA4 P22748 1/20 0.38
CA5A P35218 1/20 0.38
CA7 P43166 1/20 0.38
CA5B Q9Y2D0 1/20 0.38
NPSR1 Q6W5P4 2/20 0.38
HSD17B10 Q99714 2/20 0.38
TP53 P04637 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28736120 0.87 ALDH1A1 (0.39) ALDH1A1KDM4EPOLBTSHRNPSR1
SCHEMBL29852890 0.84 MMP1 (0.44) MMP1MMP9MMP13ADAM17VEGFA
SCHEMBL23218203 0.84 MMP1 (0.44) MMP1MMP9MMP13ADAM17VEGFA
SCHEMBL29852611 0.83 ALDH1A1 (0.47) ALDH1A1KDM4EPOLBTSHRNPSR1
SCHEMBL23219165 0.83 ALDH1A1 (0.47) ALDH1A1KDM4EPOLBTSHRNPSR1
SCHEMBL23218609 0.81 MEN1 (0.37) ALDH1A1KDM4EPOLBHSD17B10SMN1; SMN2
SCHEMBL29852778 0.80 ALDH1A1 (0.40) MMP1MMP9MMP13ADAM17VEGFA
SCHEMBL23218587 0.80 ALDH1A1 (0.40) MMP1MMP9MMP13ADAM17VEGFA
SCHEMBL16529559 0.79 MMP1 (0.53) MMP1MMP9MMP13ADAM17VEGFA
SCHEMBL23218137 0.77 PDCD1 (0.35) ALDH1A1KDM4ETSHRSMN1; SMN2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12558341-B2 Oral complement factor D inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2026-02-24 US disclosed
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2025-06-12 US disclosed
EP-4041238-A1 ORAL COMPLEMENT FACTOR D INHIBITORS Biocryst Pharmaceuticals, Inc. (US) 2022-08-17 EP disclosed
CN-114502168-A Oral complement factor D inhibitors 拜奥克里斯特制药公司 2022-05-13 CN disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12558341-B2 Oral complement factor D inhibitors CFD, CFH, CFB MMP1 1357/4885MMP9 538/4885MMP13 438/4885
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS CFD, CFH, CFB MMP1 1045/4885MMP9 640/4885MMP13 913/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.